- Home
- DFTX vs PRGS Comparison
DFTX vs PRGS Comparison
Compare DFTX & PRGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DFTX | PRGS |
|---|---|---|
| Founded | N/A | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Computer Software: Prepackaged Software |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | DFTX | PRGS |
|---|---|---|
| Price | $18.27 | $31.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $40.25 | ★ $64.60 |
| AVG Volume (30 Days) | ★ 1.5M | 869.0K |
| Earning Date | 05-04-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.79 |
| EPS | N/A | ★ 1.66 |
| Revenue | N/A | ★ $397,572,000.00 |
| Revenue This Year | N/A | $3.60 |
| Revenue Next Year | N/A | $1.28 |
| P/E Ratio | ★ N/A | $18.80 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.62 | $30.89 |
| 52 Week High | $19.67 | $65.50 |
Technical Indicators
Market Signals| Indicator | DFTX | PRGS |
|---|---|---|
| Relative Strength Index (RSI) | 54.79 | 27.18 |
| Support Level | $16.26 | N/A |
| Resistance Level | $19.62 | $43.81 |
| Average True Range (ATR) | 0.97 | 1.39 |
| MACD | 0.00 | -0.62 |
| Stochastic Oscillator | 51.06 | 6.84 |
Price Performance
Historical ComparisonAbout DFTX Definium Therapeutics Inc. Common Shares
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).
About PRGS Progress Software Corporation (DE)
Progress Software Corp provides software operate in one operating segment: software products for the development, deployment, and management of responsible, AI-powered applications and digital experiences. The following are products: Chef, Corticon, Data Direct, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, WhatsUp Gold. Geographical regions include the United States, Canada, EMEA, Latin America, and Asia Pacific.